Dr. Kalambakas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Bayer Corporation
100 Bayer Blvd
Whippany, NJ 07981Phone+1 908-967-1525
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Pediatric Hematology/Oncology, 2000 - 2003
University at BuffaloResidency, Pediatrics, 1997 - 2000
American University of the Caribbean School of MedicineClass of 1996
Certifications & Licensure
NJ State Medical License 2003 - 2025
Publications & Presentations
PubMed
- 4 citationsAnalysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R 2) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin ly...Koji Izutsu, Yosuke Minami, Noriko Fukuhara, Yasuhito Terui, Tatsuro Jo
International Journal of Hematology. 2020-03-01 - 232 citationsAUGMENT: A Phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphomaJohn P. Leonard, Marek Trneny, Koji Izutsu, Nathan Fowler, Xiaonan Hong
Journal of Clinical Oncology. 2019-03-21 - 34 citationsEltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 studyEric S. Winer, Howard Safran, Boguslawa Karaszewska, Sebastian Bauer, Dilawar Khan
International Journal of Hematology. 2017-09-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
